Winch Advisory Services LLC cut its holdings in Stryker Co. (NYSE:SYK) by 1.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,311 shares of the medical technology company’s stock after selling 198 shares during the period. Stryker comprises 1.3% of Winch Advisory Services LLC’s holdings, making the stock its 22nd largest holding. Winch Advisory Services LLC’s holdings in Stryker were worth $2,400,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of SYK. FMR LLC lifted its position in shares of Stryker by 4.8% in the 3rd quarter. FMR LLC now owns 5,581,594 shares of the medical technology company’s stock worth $991,737,000 after purchasing an additional 253,732 shares during the period. Capital International Investors purchased a new stake in shares of Stryker in the 3rd quarter worth approximately $831,822,000. Alliancebernstein L.P. lifted its position in shares of Stryker by 61.1% in the 3rd quarter. Alliancebernstein L.P. now owns 2,448,502 shares of the medical technology company’s stock worth $435,050,000 after purchasing an additional 928,279 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of Stryker by 25.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,684,169 shares of the medical technology company’s stock worth $299,243,000 after purchasing an additional 346,040 shares during the period. Finally, Capital World Investors lifted its position in Stryker by 987.2% during the third quarter. Capital World Investors now owns 1,657,979 shares of the medical technology company’s stock valued at $294,590,000 after acquiring an additional 1,505,479 shares during the last quarter. Hedge funds and other institutional investors own 74.99% of the company’s stock.
A number of research firms recently commented on SYK. Zacks Investment Research raised shares of Stryker from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research report on Monday, November 26th. Oppenheimer set a $170.00 target price on shares of Stryker and gave the company a “hold” rating in a research report on Friday, November 9th. Needham & Company LLC reissued a “hold” rating on shares of Stryker in a research report on Friday, November 9th. Deutsche Bank started coverage on shares of Stryker in a research note on Wednesday, January 2nd. They set a “buy” rating and a $179.00 price target on the stock. Finally, Evercore ISI upgraded shares of Stryker from an “in-line” rating to an “outperform” rating and set a $156.75 price target on the stock in a research note on Wednesday, January 2nd. Seven research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Stryker has an average rating of “Buy” and a consensus price target of $185.37.
Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.15 by $0.03. Stryker had a net margin of 26.12% and a return on equity of 27.60%. The business had revenue of $3.80 billion for the quarter, compared to analyst estimates of $3.73 billion. On average, sell-side analysts predict that Stryker Co. will post 8.12 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Thursday, March 28th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 1.13%. Stryker’s payout ratio is currently 28.45%.
In other news, insider Timothy J. Scannell sold 9,332 shares of the stock in a transaction on Tuesday, December 18th. The shares were sold at an average price of $161.60, for a total value of $1,508,051.20. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Michael Damon Hutchinson sold 15,995 shares of the firm’s stock in a transaction on Friday, February 8th. The shares were sold at an average price of $180.49, for a total transaction of $2,886,937.55. The disclosure for this sale can be found here. Insiders sold 43,259 shares of company stock worth $7,515,747 in the last quarter. Company insiders own 7.30% of the company’s stock.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
See Also: How liquidity affects the bid-ask spread
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.